CGTX
$1.15
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.
Intraday
Recent News
Will Cognition Therapeutics (NASDAQ:CGTX) Spend Its Cash Wisely?
There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Cognition Therapeutics...
Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical Stocks This Year?
Here is how ANI Pharmaceuticals (ANIP) and Cognition Therapeutics, Inc. (CGTX) have performed compared to their sector so far this year.
Cognition Therapeutics (CGTX) Moves to Buy: Rationale Behind the Upgrade
Cognition Therapeutics (CGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cognition Therapeutics, Inc. (CGTX) Retains Buy Rating on START Study Progress
Cognition Therapeutics, Inc. (NASDAQ:CGTX) is among the fundamentally strong penny stocks to invest in. H.C. Wainwright has maintained a $3.00 price target for Cognition Therapeutics, Inc. (NASDAQ:CGTX), with an unchanged Buy rating. This potential upside of nearly 640% represents the company’s Phase 2 START Study enrollment success that exceeded 50%. The START Study (NCT05531656), which […]
We're A Little Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...